

Annual Review of Bladder Control Drugs - Fiscal Year 2009

Oklahoma Health Care Authority
April 2010

Prior Authorization Criteria

Tier 2 Authorization Criteria:

1. Trial of one Tier 1 medication that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 1 drugs lack.

Tier 3 Authorization Criteria:

1. Trial of all Tier 2 medications that yielded inadequate clinical response or adverse effects, or
2. A unique indication which the Tier 2 drugs lack.

Members who are currently stabilized on a Tier 2 or Tier 3 medication will be allowed to continue their current treatment without prior authorization.

Bladder Control Medications		
Tier 1	Tier 2**	Tier 3
Flavoxate (Urispas ®) Oxybutynin (Ditropan ®) Tolterodine (Detrol ®)	Darifenacin (Enablex ®) Trospium (Sanctura ™) Trospium (Sanctura XR ™)	Oxybutynin ER Tabs (Ditropan XL ®) Oxybutynin Patch (Oxytrol ®) Oxybutynin Gel (Gelnique ™) Tolterodine ER Tabs (Detrol LA ®) Fesoterodine (Toviaz ™) Solifenacin (VESIcare ®)

*hyoscyamine can be used as adjuvant therapy only. By itself, it will not count as a tier-1 trial.


**Tier 2 due to supplemental rebate agreement.

Utilization


For the period of July 2008 through June 2009, a total of 3,084 members received bladder control drugs through the SoonerCare program.

Fiscal Year	Total Members	Total Claims	Total Paid	Paid per Claim	Per-Diem	Total Units	Total Days
2008	2,866	12,038	\$1,067,942.78	\$88.71	\$2.65	791,388	402,448
2009	3,084	12,672	\$1,244,031.23	\$98.17	\$2.95	809,014	421,169
% Change	7.60%	5.30%	16.50%	10.70%	11.30%	2.20%	4.70%
Change	218	634	\$176,088.45	\$9.46	\$0.30	17,626	18,721

Demographics



Top 10 Prescribers by number of claims



Prior Authorization Activity

A total of 257 petitions were submitted for this category during fiscal year 2009.

Status	Total PA Count
Approved	101
Denied	85
Incomplete	71

Market News

- Fesoterodine (Toviaz™) – was approved in October 2008 and added to Tier 3 of the category.
- Gelnique™ – oxybutynin topical gel was approved in January 2009 and was added to Tier 3 of the category.
- Detrol & Detrol LA – anticipated patent expiration in March 2012.
- Oxytrol's patent is expected to expire in December 2010.

Recommendations

The College of Pharmacy recommends no changes at this time.

Utilization by Individual Product

Product	# of Claims	Total Units	Total Days	Unduplicated Members	Per Diem	Total Cost
Enablex 7.5 mg	271	10,765	9,704	90	\$4.59	\$44,503.82
Enablex 15 mg	270	10,034	9,104	69	\$4.54	\$41,305.02
Flavoxate 100 mg	182	8,968	2,808	115	\$2.99	\$8,398.66
Oxytrol 2.9mg/24h	21	216	714	7	\$4.45	\$3,179.18
Oxybutynin 5 mg	3,339	236,010	102,316	957	\$0.35	\$36,181.97
Oxybutynin 5 mg/5ml	846	224,528	22,684	295	\$0.44	\$10,065.53
Oxybutynin ER 5 mg	189	8,889	6,363	47	\$2.55	\$16,210.51
Oxybutynin ER 10 mg	779	32,448	26,248	137	\$2.29	\$60,234.65
Oxybutynin ER 15 mg	310	15,055	10,977	58	\$2.67	\$29,352.50
Ditropan XL 15 mg	1	90	90	1	\$3.72	\$335.10
Hyoscyamine 0.15 mg	15	1,325	410	6	\$1.20	\$492.85
VESIcare 5 mg	805	31,652	29,078	221	\$4.56	\$132,598.83
VESIcare 10 mg	514	20,053	17,199	128	\$4.94	\$85,035.42
Detrol 1 mg	89	4,625	2,599	31	\$4.11	\$10,677.15
Detrol 2 mg	539	32,537	16,882	145	\$4.51	\$76,079.69
Detrol LA 2 mg	491	18,952	17,367	136	\$4.44	\$77,161.31
Detrol LA 4 mg	3,840	145,110	140,725	1,018	\$4.16	\$585,358.15
Sanctura 20 mg	34	2,212	1,106	6	\$4.42	\$4,886.64
Sanctura XR 60 mg	129	5,305	4,555	39	\$4.60	\$20,947.85
Toviaz 4 mg	4	120	120	4	\$4.28	\$513.20
Toviaz 8 mg	4	120	120	3	\$4.28	\$513.20
Total	12,672	809,014	421,169	3,084*	\$2.95	\$1,244,031.23

*Total unduplicated members for the time period.